Glaxo snags $41M in Defense Department deal

GlaxoSmithKline has snagged a deal with the Department of Defense to develop a new class of antibiotics that can be used against biothreats as well as hospital-acquired infections. In the deal, Glaxo will get $41 million from the DoD, though it notes it will be spending plenty of its own money on the project. "The research will focus on such Gram negative pathogens as Pseudomonas, Klebsiella and Acinetobacter, which are increasingly resistant to all known classes of antibiotics," Glaxo said.

"The Department of Defense is excited about the opportunity of teaming with GSK and leveraging their capabilities and resources to develop antibacterial compounds for Gram negative biothreat agents," said Lieutenant Colonel Calvin Carpenter at the Defense Threat Reduction Agency. "This research is needed to identify and deliver antibacterials from entirely new classes to defend against potential biothreat outbreaks and hospital-acquired infections." 

- check out the release for more information

Related Articles:
Drug-resistant superbugs drive blockbuster antibacterials. Report
VA program slashes MRSA infection rates. Report
Riled investors look for big changes at GSK. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.